A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with ...
Data from the IMvigor011 phase 3 study shows that adjuvant atezolizumab (Tecentriq) significantly boosts the reduction and clearance of circulating tumor DNA (ctDNA). Presented at ...
ImmunityBio has reached a significant milestone in a pivotal Phase 2 study for bladder cancer. The biopharmaceutical company has completed patient enrollment for its QUILT 2.005 trial ahead of ...
Protara Therapeutics (TARA) lost ~22% on Tuesday after the company posted updated interim data from a mid-stage trial for its lead candidate TARA-002 in patients with non-muscle invasive bladder ...
Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...
Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small ...
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference ...
Staying fit and active has long been associated with better heart and overall health. It might also improve the chances of survival for people with some forms of cancer. A study published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results